Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Over $42 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

Published 22/11/2022, 13:44
© Reuters.  Over $42 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
GHL
-
ACRV
-

Benzinga - Although US stocks closed mostly lower on Monday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Acrivon Therapeutics

  • The Trade: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) Director Rajeev Shah acquired a total of 4,810,508 shares an average price of $12.50. To acquire these shares, it cost around $42.37 million.
  • What’s Happening: The company recently priced its initial public offering of 7,550,000 shares at $12.50 per share.
  • What Acrivon Therapeutics Does: Acrivon Therapeutics is clinical stage biopharmaceutical company.

Ryan Specialty

  • The Trade: Ryan Specialty Holdings, Inc. (NYSE: RYAN) CEO Patrick Ryan acquired a total of 288,038 shares at an average price of $38.26. To acquire these shares, it cost around $11.02 million.
  • What’s Happening: The company recently posted Q3 results.
  • What Ryan Specialty Does: Ryan Specialty Holdings Inc, formerly Ryan Specialty Group Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents and carriers.
Don’t forget to check out our premarket coverage here .

Also check this: Amazon (NASDAQ:AMZN) To $119? Here Are 5 Other Price Target (NYSE:TGT) Changes For Tuesday

Greenhill & Co

  • The Trade: Greenhill & Co., Inc. (NYSE: GHL) Chairman and CEO Scott L Bok bought a total of 47,850 shares at an average price of $10.09. To acquire these shares, it cost around $482.99 thousand.
  • What’s Happening: Greenhill recently reported better-than-expected Q3 sales results.
  • What Greenhill & Co Does: Greenhill & Co Inc is an independent investment bank that provides financial and strategic advice on significant domestic and cross-border mergers and acquisitions, divestitures, restructurings, financings, capital raising and other transactions to a diverse client base, including corporations, partnerships, institutions and governments globally.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.